BiotechTube
Windward Bio

Windward Bio

Basel, Switzerland· Est.
windwardbio.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $205.5M

Overview

Windward Bio is a newly launched, well-funded private biotech with a clear focus on immunology. The company emerged in January 2025 with a substantial $200M Series A financing and is led by a seasoned executive team with a strong track record of company creation and exits. Its strategy centers on engineering long-acting antibodies against established targets like TSLP and IL-13, with two clinical-stage programs aimed at improving dosing convenience and efficacy in diseases such as asthma and COPD. The company is positioned to advance its pipeline rapidly, leveraging its team's deep development and commercialization expertise.

ImmunologyRespiratoryDermatology

Technology Platform

Engineering of long-acting monoclonal and bispecific antibodies with half-life extension (HLE) and silenced Fc effector function.

Funding History

2
Total raised:$205.5M
PIPE$200M
Seed$5.5M

Opportunities

The large and growing markets for severe asthma, COPD, and atopic dermatitis present significant commercial opportunities.
Successfully developing a long-acting anti-TSLP with a superior dosing profile could capture substantial market share in asthma and be first-in-class in COPD.
The bispecific approach targeting TSLP and IL-13 could address broader patient populations and offer best-in-class efficacy.

Risk Factors

Key risks include clinical failure or underwhelming data for lead candidate WIN378 in its ongoing Phase 2 trial, intense competition from established and emerging biologics in immunology, and execution risk in simultaneously advancing two clinical programs.
The company's high valuation post-Series A also sets a high bar for future financing or exit.

Competitive Landscape

Windward Bio operates in the highly competitive immunology space, directly competing with AstraZeneca/Amgen's tezepelumab (anti-TSLP) in asthma and numerous anti-IL-13 agents (e.g., lebrikizumab, tralokinumab) in dermatology and respiratory diseases. Its differentiation strategy relies on engineering for less frequent dosing (long-acting) and optimized safety (Fc silenced), rather than novel target discovery.

More companies in Switzerland →